ArticleFrontiers in endocrinology2025
Inhibition of histone methyltransferase G9a promotes the osteogenic potential of bone-derived stem cells in diabetic-osteoporosis by regulating the LINC00657/miR-204-5p/IGFBP5 pathway.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bone mesenchymal stem cells (BMSCs) from patients with diabetes often exhibit reduced osteogenic potential. This study aimed to investigate the mechanism of action of G9a, known as euchromatic histone lysine methyltransferase 2 (EHMT2), identify its key responsive long non-coding RNA in diabetic osteoporosis (DOP), and evaluate the effectiveness of the G9a inhibitor (UNC0638). Methods: The expression level of G9a in bone-derived MSCs (BMSCs) from osteoporosis patients with or without T2DM (T2DM-BMSCs, CON-BMSCs) was detected, and osteogenic differentiation was evaluated by osteogenic genes, ALP activity and calcification level. The key lncRNA, LINC00657, was screened based on previous transcriptome sequencing, qPCR and gene overexpression assay. The downstream miRNA and the target gene of LINC00657 were identified through transcriptome sequencing, bioinformatics analysis, dual luciferase reporter assay and gene overexpression assay. Rat DOP was constructed, and micro-CT, histochemical staining, immunofluorescence and qPCR were used to investigate the mechanism of UNC0638. Results: G9a expression was increased and LINC00657 expression was decreased in T2DM-BMSCs, compared with CON-BMSCs. UNC0638 treatment improved the osteogenic potential of T2DM-BMSCs and reversed the downregulation of LINC00657. LINC00657 overexpression reverses the inhibitory effect of EHMT2 on osteogenic differentiation. miR-204-5p and IGFBP5 were screened as downstream molecules of LINC00657. LINC00657 was able to sponge miR-204-5p and upregulated IGFBP5 expression, thereby promoting osteogenesis in T2DM-BMSCs. UNC0638 treatment alleviated osteoporosis in DOP rats, whereas LINC00657 knockdown inhibited its effect Conclusions: G9a inhibits the osteogenic potential of T2DM-BMSCs by regulating the LINC00657/miR-204-5p/IGFBP5 pathway and UNC0638 may be a potential agent for DOP treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.